The major limitation is that over 50% of GBM patients treated with TMZ develop resistance [22] through several mechanisms, such as the activation of repair enzymes such as O6-methylguanine-DNA methyltransferase (MGMT). The gene discussed is MGMT; the disease is glioblastoma.